Dr. Lal Pathlabs Ltd.

NSE: LALPATHLAB | BSE: 539524 | ISIN: INE600L01024 | Industry: Healthcare Services
| Expensive Rocket
1910.6000 -59.10 (-3.00%)
NSE Oct 13, 2026 15:31 PM
Volume: 95,924
 

1910.60
-3.00%
Geojit BNP Paribas
EBITDA rose 16.4% YoY to Rs. 179cr, and the margin expanded 140 basis points (bps) YoY to 27.2%, driven by sustained volume growth, network expansion and a favourable mix, combined with the efficient hub-and-spoke model and technology...
Emkay increased Buy price target of Dr. Lal Pathlabs Ltd. to 2100.0 on 24 Sep, 2026.
More from Dr. Lal Pathlabs Ltd.
Recommended